Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29827071 | 1.00 | NR1H2 (0.55) | NR1H2PDE4BUSP30USP2SMN1; SMN2 | |
| SCHEMBL29826963 | 1.00 | NR1H2 (0.55) | NR1H2PDE4BUSP30USP2SMN1; SMN2 | |
| SCHEMBL26906071 | 1.00 | NR1H2 (0.55) | NR1H2PDE4BUSP30USP2SMN1; SMN2 | |
| SCHEMBL21216437 | 1.00 | NR1H2 (0.55) | NR1H2PDE4BUSP30USP2SMN1; SMN2 | |
| SCHEMBL2251816 | 0.88 | NR1H2 (0.49) | NR1H2PDE4BUSP2SMN1; SMN2MEN1 | |
| SCHEMBL22413340 | 0.88 | NR1H2 (0.49) | NR1H2PDE4BUSP2SMN1; SMN2MEN1 | |
| SCHEMBL22413339 | 0.88 | NR1H2 (0.49) | NR1H2PDE4BUSP2SMN1; SMN2MEN1 | |
| SCHEMBL2251815 | 0.88 | NR1H2 (0.49) | NR1H2PDE4BUSP2SMN1; SMN2MEN1 | |
| SCHEMBL30837088 | 0.88 | NR1H2 (0.48) | NR1H2PDE4BUSP30USP2SMN1; SMN2 | |
| SCHEMBL13110458 | 0.88 | NR1H2 (0.48) | NR1H2PDE4BUSP30USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240408093-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. | 2024-12-12 | — | — | US | disclosed |
| WO-2023067354-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023059609-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2023-04-13 | — | — | WO | disclosed |
| WO-2023059605-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2023-04-13 | — | — | WO | disclosed |
| EP-3746435-B1 | SUBSTITUTED QUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER (US) | 2022-08-03 | — | — | EP | disclosed |
| EP-3746435-B1 | SUBSTITUTED QUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER (US) | 2022-08-03 | — | — | EP | disclosed |
| EP-3536685-B1 | BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AND THEIR USE AS IRAK4 INHIBITORS | PFIZER (US) | 2022-02-16 | — | — | EP | disclosed |
| US-10662204-B2 | Substituted quinazoline and pyridopyrimidine derivatives useful as anticancer agents | PFIZER INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-20190233440-A1 | Substituted Quinazoline and Pyridopyrimidine Derivatives Useful as Anticancer Agents | PFIZER INC. (US) | 2019-08-01 | — | — | US | disclosed |
| EP-2758402-B9 | PYRROLOPYRIMIDINE AND PURINE DERIVATIVES | PFIZER (US) | 2016-09-14 | — | — | EP | disclosed |
| US-20150203502-A1 | PYRROLOPYRIMIDINE AND PURINE DERIVATIVES | PFIZER (US) | 2015-07-23 | — | — | US | disclosed |
| US-9040547-B2 | Pyrrolopyrimidine and purine derivatives | PFIZER INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-9040547-B2 | Pyrrolopyrimidine and purine derivatives | PFIZER INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-9040547-B2 | Pyrrolopyrimidine and purine derivatives | PFIZER INC. (US) | 2015-05-26 | — | — | US | disclosed |
| WO-2014140989-A2 | COMBINATION OF AN EGFR T790M INHIBITOR AND AN EGFR INHIBITOR FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER | PFIZER INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| EP-2758402-A1 | PYRROLOPYRIMIDINE AND PURINE DERIVATIVES | Pfizer Inc (US) | 2014-07-30 | — | — | EP | disclosed |
| US-20130079324-A1 | PYRROLOPYRIMIDINE AND PURINE DERIVATIVES | PFIZER INC. | 2013-03-28 | — | — | US | disclosed |
| WO-2013042006-A1 | PYRROLOPYRIMIDINE AND PURINE DERIVATIVES | PFIZER INC. (US) | 2013-03-28 | — | — | WO | disclosed |
| WO-2013042006-A1 | PYRROLOPYRIMIDINE AND PURINE DERIVATIVES | PFIZER INC. (US) | 2013-03-28 | — | — | WO | disclosed |
| US-20130079324-A1 | PYRROLOPYRIMIDINE AND PURINE DERIVATIVES | PFIZER INC. | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240408093-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | FGFR3, FGFR1, ERBB3 | NR1H2 2719/4885PDE4B 4211/4885USP30 1064/4885 |
| US-10662204-B2 | Substituted quinazoline and pyridopyrimidine derivatives useful as anticancer agents | DPYD, PDXK, TYMP | NR1H2 3754/4885PDE4B 1025/4885USP30 4340/4885 |
| US-20190233440-A1 | Substituted Quinazoline and Pyridopyrimidine Derivatives Useful as Anticancer Agents | DPYD, TYMP, TOP2A | NR1H2 4137/4885PDE4B 2116/4885USP30 4424/4885 |
| US-20130079324-A1 | PYRROLOPYRIMIDINE AND PURINE DERIVATIVES | TYMP, DPYD, TYMS | NR1H2 4568/4885PDE4B 814/4885USP30 3902/4885 |
| US-20150203502-A1 | PYRROLOPYRIMIDINE AND PURINE DERIVATIVES | TYMP, DPYD, TYMS | NR1H2 4568/4885PDE4B 814/4885USP30 3902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.